DOCSLIB.ORG

6Th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25Th - 26Th Sept 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
6Th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25Th - 26Th Sept 2014 6th Annual Translational Medicine Conference ‘Personalising Health and Care’ Date: 25th and 26th September 2014 | Venue: City Hotel, Derry/Londonderry, N.Ireland, UK 1 6th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25th - 26th Sept 2014 Conference Sponsors 2 6th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25th - 26th Sept 2014 Contents Page Conference Programme .................................................................................... 4 Biographies .......................................................................................................... 6 - 9 Delegate List ........................................................................................................ 10 - 12 Bio-Entrepreneur Programme........................................................................ 13 About C-TRIC ....................................................................................................... 14 - 15 Abstracts Poster Presentations................................................................. 16 - 42 Abstracts Oral Presentations................................................................. 43 Abstracts Poster List................................................................. 44 3 6th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25th - 26th Sept 2014 ‘Personalising Health and Care’ - Conference Programme Day One Thursday 25th Sept 1:00 pm Registration and Tea/Coffee 4.30 pm Oral Presentations Parallel Sessions 2:00 pm Welcome and Opening Address Brenda Stevenson, Mayor of Derry Chaired by Chaired by Prof Tony Bjourson, Dr David Brownlee, HSC 2:05 pm Barry Henderson, Business Development Director, Biomedical Innovations Manager, C-TRIC Sciences Research ‘Supporting R&D in Personalised Health and Care’ Institute & Director, Northern Ireland 2:15 pm Dr Penny Wilson Innovation Platform Lead for Stratified Medicine Centre, University of Stratified Medicine, TSB, UK Ulster ‘Supporting Translational Medicine and Healthcare Innovation in the UK’ 5.00 pm Stratified/Precision Technology & novel 2.35 pm Supporting Life and Health Sciences in NI & ROI Medicine 1 approaches….1 Dr Clive Wolsley, Health & Social Care (R&D 5.15 pm Stratified/Precision Technology & novel Division), Public Health Agency Medicine 2 approaches….2 Sam Kinghan, Invest Northern Ireland 5.30 pm Stratified/Precision Technology & novel Patricia McCrory, EU Thematic Lead (Health), Medicine 3 approaches….3 Queen’s University of Belfast 5.45 pm Stratified/Precision Technology & novel 2.55 pm Break for Tea/Coffee - Poster Viewing Session Medicine 4 approaches….4 6.00 pm Stratified/Precision Technology & novel 3.25 pm Dr Jonathan Berg, Consultant Clinical Medicine 5 approaches….5 Biochemist, Sandwells and West Birmingham Hospitals, NHS Trust, UK 6.15 pm Close ‘TPMT shows the way for routine pharmacogenomics; let’s understand why it 6.45 pm Drinks Reception/ Poster Viewing Session has been accepted into routine clinical practice’ 7.45 pm Conference Dinner 3.55 pm Dr David McEneaney, Director of the Cardiovascular Research Unit, Craigavon Area Guest Speaker Hospital Joanne Stuart, NI Science Park Foundation ‘Cardiology Futures’ Ltd (Director) 4 6th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25 - 26th Sept 2014 Conference Programme Continued... Day 2 Friday 26th Sept 1.40pm Prof Steven 1.30pm Barney Devine & David 8:30 am Registration Pennington Bolton, Word on the Ground Professor of ‘Using technology to better 9.05 am Dr Mark Beggs, Associate Director / Chief Proteomics, manage Post Traumatic Stress Operating Officer of Stratified Medicine University College Disorder (PTSD)’ Dublin, Ireland Scotland Innovation Centre ‘Development of a ‘Stratified Medicine Scotland – a National blood based protein Enterprise for Precision Medicine’ signature to stratify patients for prostate 9.35 am Professor Charles Abraham, Professor of cancer treatment. Psychology Applied to Health, University From Discovery to Clinical Diagnostics’ of Exeter ‘The Role of Behaviour Change Intervention Design 2.00pm Dr Nicholas Orr 1.45pm John Dinsmore, Health Team Leader, Innovation Lead, Centre and Evaluation in Translational Medicine’ Institute of Cancer for Practice and Healthcare Research, UK Innovation, Trinity College 10.05 am Coffee Break/ Poster Viewing Session ‘The role of genetics Dublin and genomics ‘The BREATHE Project: A study 10.20 am Ravi Rao, VP, Medicines Development in personalised of the development and use Leader and Head Unit Physician, Immuno- approaches to breast of assisted living technology inflammation Therapy Area Unit, GSK cancer prevention by informal care givers and ‘Developing new medicines: learning to take them and treatment’ people living with chronic health conditions’ personally’ 2.00pm Peter Donnelly, Chief 10.50 am Peter Weber, Professor of Nutrition, DSM Executive, BioBusiness Ltd. ‘Healthcare Technology & Nutritional Products Ltd, Switzerland Apps: Regulatory Issues’ ‘Personalising Micronutrient Intakes to benefit Human Health: Emerging Science & Consumer 2.15pm Q&A Needs’ 2.25pm Close 2.25pm Close 11.20 am Dr Hanne Albert, St Bartholomew’s 2.30pm Poster Viewing Session Hospital, UK ‘Curing Back Pain Using Antibiotics’ Better Data, Better Health, Better Care Session title TBC Lunch 12.00 - 1.00 Buffet Lunch/Poster Viewing 3.00pm Mr David Bingham Chief Executive, Business Services Organisation, NI 1.00 – 2.30 – Breakout Sessions ‘Honest Broker Service - its Role in Better Care’ Chaired Dr Maurice O’Kane Chaired Prof Jonathan Wallace, by Director R&D by University of Ulster 3.15pm Stephen Lusty, JAG’L Consulting Western Health and Tech & novel approaches ‘Building Northern Ireland’s Healthcare Social Care Trust for improved disease Analytics Capability’ Personalised/ prevention, management & Stratified Medicine patient care 3.30pm Professor Siobhan O’Neill, Psychology 1.00pm Chris Roche Chief 1.00pm Peter Devine, Head of Business Research Institute, University of Ulster Commercial Officer, Development, Intelligent ‘Using Data to Improve Outcomes in Mental Aridhia, UK Systems Research Centre, Illness and Suicide Prevention’ ‘Why Personalised University of Ulster Medicine is a Long ‘Using novel technologies, 3.45pm Panel discussion chaired by Trung Do - Tailed Business devices and intelligent Model’ systems towards improved Executive Director of Business Development healthcare’ at Partners Healthcare 1.20pm Dr Des Brennan, Life 1.15pm Kieran Daly, Chair of Sciences Interface BioBusiness 4.00pm Results of Poster Competition and Closing Group, Tyndall ‘The use of technology Remark Institute towards personalised ‘Emerging healthcare’ technology platforms 4.10pm Close for near patient genetic analysis 5 for personalised medicine’ BIOGRAPHIES Professor Charles Abraham Professor Charles Abraham is a social and health psychologist. His research focuses on improving the design and evaluation of interventions to change health behaviour patterns. The aim of his research is to optimise translation of research findings into improved healthcare practice. He employs a range of quantitative and qualitative methods and collaborates widely. He is Head of the Psychology Applied to Health (PAtH) group in the University of Exeter Medical School. The PAtH group consists of 5 core faculty, 8 research fellows and 10 doctoral students. He also hold honorary positions at Sussex, Maastricht, Nottingham and Curtin universities. He has investigated a wide range of behaviour patterns including exercise, diet, alcohol use, condom use, smoking cessation, blood and organ donation and management of chronic illnesses. He has developed and evaluated effective interventions to promote health-enhancing behaviours in a range of contexts from schools in South Africa to “Weight Watchers” classes in Poland. Charles Abraham is a practising, health psychologist (registered by the UK Health and Care Professionals Council) and between 1997 and 1999, he was the founding chair of the British Psychological Society Division of Health Psychology. In this role he led a team of psychologists who established the accreditation systems used to regulate health psychology practitioners in the UK. In 2003-2004 he was employed as a consultant in the UK Department of Health and in 2014, he was one of seven psychologists included in a list of the leading 100 practising scientists in the UK; a list generated for the first time by the UK Science Council. In the UK the National Institute for Health and Care Excellence (NICE) sets standards for quality healthcare and produces guidance on medicines, treatments and procedures. Charles Abraham has served on two NICE guidance development groups on health behaviour change in 2003/4 and 2012/13. In 2011/12 he served as scientific advisor to House of Lords Select Committee on Science and Technology, Inquiry into Behaviour Change which made 32 recommendations to government including advocating greater investment in evaluation of interventions. Dr Mark Beggs Dr Mark Beggs is Chief Operating Officer for Stratified Medicine Scotland based in Glasgow UK. SMS-IC is an Industry, Academia, NHS collaboration developing a commercial capability in Stratified Medicine. SMS-IC is based in Scotland, UK and capitalises on a strong academic research base in major disease areas coupled with unique NHS e-Health Records and industrial quality NextGen Sequencing and hosted analytics capabilities provided
Load more

Recommended publications
  • Alderley Park the Future As a World-Class Life Science Facility Planning Application Summary Document
    DECEMBER 2015 ALDERLEY PARK THE FUTURE AS A WORLD-CLASS LIFE SCIENCE FACILITY PLANNING APPLICATION SUMMARY DOCUMENT Alderley Park is a world-class Life Science research and development (R&D) facility. The site currently houses around 190,000 sq m of premier scientific laboratory space, offices, restaurants, cafes, conferencing space and energy plant, set in 400 acres of parkland. As a centre for scientific research, it is one of the few facilities in the country with a comprehensive offering to support drug discovery and development. It was AstraZeneca’s global lead centre for cancer research, employing at its peak up to 10,000 people in highly skilled jobs. These facilities at Alderley Park are high-quality A planning application has been submitted to and high-tech, and require significant ongoing Cheshire East Council for future development investment to retain them. £550 million has been at Alderley Park. The planning application invested in Alderley Park since 1997 and further, has been allocated the reference number major investment is required to repurpose the site 15/5401M. from single to multi-occupier use, maintain the facilities and cover ongoing overheads. This summary document sets out the key elements of the proposals. ILLUSTRATIVE MASTERPLAN SIGNIFICANT INVESTMENT PROPOSED OVER THE NEXT 10 YEARS In March 2013, AstraZeneca announced The site was purchased by Bruntwood/MSP, its decision to relocate its R&D facilities to part of Alderley Park Ltd who now wish to Cambridge, leading to uncertainty over the secure the future of the site, retaining talent and future of Alderley Park and its role in the local jobs, by taking forward the Taskforce’s vision.
    [Show full text]
  • Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting
    Author Manuscript Published OnlineFirst on December 16, 2013; DOI: 10.1158/1535-7163.MCT-13-0420 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Fully Human Anti-Hedgehog Antibodies Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling. Authors: Neil R. Michaud1*, Youzhen Wang1, Kristen McEachern1, Jerold J. Jordan1, Anne Marie Mazzola1, Axel Hernandez1, Sanjoo Jalla2, Jon W. Chesebrough2, Mark J. Hynes3, Matthew Belmonte 1, Lidong Wang3, Jaspal S. Kang4#, Jelena Jovanović5, Naomi Laing1, David W. Jenkins1, Elaine Hurt2, Meina Liang6, Christopher Frantz7, Robert E. Hollingsworth2, Diane M. Simeone3, David C. Blakey8, and Vahe Bedian1* Authors’ affiliation: 1Oncology iMED, AstraZeneca-R&D Boston, Waltham, MA 2Oncology Research, MedImmune LLC, Gaithersburg, MD 3Translational Oncology Program, University of Michigan, Ann Arbor, MI; 4Amgen British Columbia, Burnaby, BC, Canada 5Lead Generation- Research, Medimmune LLC, Granta Park, Cambridge, UK 6Clinical Pharmacology and DMPK, MedImmune LLC, Hayward, CA 7Biologics Safety Assessment, MedImmune LLC, Mountain View, CA 8Oncology iMed, AstraZeneca, Alderley Park, Macclesfield. UK #Current address: Paul Kang, CSO, Innovative Targeting Solutions Inc., Burnaby BC, Canada *corresponding authors: Neil R. Michaud, Ph.D. Oncology iMED AstraZeneca-R&D Boston Waltham, MA 02451 e-mail: [email protected] Vahe Bedian Ph.D. Oncology iMED AstraZeneca-R&D Boston Waltham, MA 02451 phone:781-839-4613 e-mail: [email protected] Running title: Fully Human Anti-Hedgehog Antibodies Key Words: Hedgehog, Antibody, Xenograft, XenoMouse, cancer stem cells Grant Support: This work was funded by AstraZeneca PLC and MedImmune LLC. Disclosure of Potential Conflicts of Interest: There are no potential conflicts of interest.
    [Show full text]
  • Alderley Park Development Framework
    Alderley Park Development Framework Consultation Draft - January 2015 0i 2 Contents 1 Introduction 2 The Site 3 Planning Policy 4 Design Guidance 5 Indicative Masterplan 6 Planning Applications 7 Summary and Next Steps Appendices 3 1 Introduction Alderley Park, a research and development site The Taskforce commissioned a study to establish the new vision for the site. It allocates Alderley Park as an renowned for the discovery and development of potential future demand from the life science sector, for ‘opportunity site’, seeking to promote and encourage the innovative new medicines, is a key part of the North the world class laboratory and office space on site1. That development of the Life Science Park whilst recognising West Life Science Ecosystem. Opening more than 40 study indicated that whilst there would not by any means that there is likely to be a need for a degree of flexibility years ago, the site has a rich heritage of important be an instant demand for all the site’s facilities, with an regarding land uses to deliver, grow and sustain the Life advancements in medical treatments, including a appropriate business model, there is potential to build on Science Park vision. number of anti-cancer treatments. As the lead centre the BioHub concept, repurposing the site to offer facilities Until the adoption of the CELPS, the current development for cancer research, Alderley Park currently houses which complement existing life science resources across plan for the area remains the Macclesfield Borough the global Advanced Lead Discovery Centre, and its the region, such that Alderley Park can continue to be a Local Plan.
    [Show full text]
  • Directions to Alderley Park Conference Centre
    Directions to Alderley Park Conference Centre Travel by rail Travel by road Travel by air A regular shuttle service from Alderley Alderley Park is centrally located on Alderley Park is located within 20 minutes Park provides convenient transfer from both the UK’s North/South and East/ drive time on uncongested roads to nearby Wilmslow and Macclesfield mainline West motorway network. The main M6 Manchester Airport, which serves more stations, connecting with direct services motorway is just 20 minutes’ drive away destinations than any other airport in to London that run every 20 minutes and on uncongested roads. Manchester city the UK. This top 20 international airport take under two hours. Manchester is a key centre can be accessed in 40 minutes and handles over 22m passengers every year rail hub on the West Coast mainline linking Liverpool and Leeds can be reached within to over 220 worldwide destinations allowing London with Scotland as well as being the one hours’ drive time, with Birmingham comprehensive direct flight access to main arterial rail link between England, two hours drive time from site. On-site car Europe, the US and the Far East. In addition Wales and Scotland. parks at Alderley Park can accommodate Liverpool airport is 40 miles away and approximately 4,000 vehicles. Birmingham West Midlands is 71 miles away. Regional map Local map TO MANCHESTER AIRPORT M6 to Preston, M62 to Leeds MANCHESTER Carlisle, Scotland ROAD 4 3 A34 - TO M66 A M6 Rochdale M60 J3 & MANCHESTER Heywood Bury M62 W A T E R L A Bolton N E 8 WILMSLOW
    [Show full text]
  • Large-Scale Isolation of Human Skeletal Muscle Satellite Cells from Post-Mortem Tissue and Development of Quantitative Assays to Evaluate Modulators of Myogenesis
    J Cachexia Sarcopenia Muscle (2013) 4:157–169 DOI 10.1007/s13539-012-0097-z ORIGINAL ARTICLE Large-scale isolation of human skeletal muscle satellite cells from post-mortem tissue and development of quantitative assays to evaluate modulators of myogenesis Ian C. Scott & Wendy Tomlinson & Andrew Walding & Beverley Isherwood & Iain G. Dougall Received: 24 July 2012 /Accepted: 25 November 2012 /Published online: 24 January 2013 # Springer-Verlag Berlin Heidelberg 2013 Abstract Methods Satellite cells were isolated by digestion of post- Background During aging, there is a decreased ability to mortem skeletal muscle and selection using anti-CD56 maintain skeletal muscle mass and function (sarcopenia). MicroBeads. CD56+ cell-derived myotubes were quantified Such changes in skeletal muscle are also co-morbidities by high content imaging of myosin heavy chains. TaqMan- of diseases including cancer, congestive heart failure polymerase chain reaction arrays were used to quantify expres- and chronic obstructive pulmonary disease. The loss of sion of 41 selected genes during differentiation. The muscle mass results in decreased strength and exercise effects of activin receptor agonists and tumour necrosis tolerance and reduced ability to perform daily activities. factor alpha (TNFα) on myogenesis and gene expres- Pharmacological agents addressing these pathologies sion were characterised. could have significant clinical impact, but their identifi- Results Large-scale isolation of CD56+ cells enabled devel- cation requires understanding of mechanisms driving opment of a quantitative myogenesis assay with maximal myotube formation (myogenesis) and atrophy and pro- myotube formation 3 days after initiating differentiation. vision of relevant assays. The aim of this study was to Gene expression analysis demonstrated expression of 19 develop robust in vitro methods to study human genes changed substantially during myogenesis.
    [Show full text]
  • Cardiovascular Safety Risk Assessment for New Candidate Drugs from Functional and Pathological Data
    Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data 14th & 15th November 2013 Alderley Park Conference Centre, Cheshire, UK The 28th annual meeting of the British Society of Toxicological Pathology (BSTP) held jointly with the Safety Pharmacology Society (SPS) Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data th th 14 & 15 November 2013, Alderley Park Conference Centre, UK 28th ANNUAL SCIENTIFIC MEETING of the BRITISH SOCIETY OF TOXICOLOGICAL PATHOLOGY held jointly with the SAFETY PHARMACOLOGY SOCIETY I am delighted to welcome you to the 28th annual meeting of the British Society of Toxicological Pathology (BSTP) held jointly with the Safety Pharmacology Society (SPS) and sponsored by the Health and Environmental Sciences Institute (HESI) at The Alderley Park Conference Centre, Cheshire, UK on 14th and 15th November 2013. The excellent programme on offer at this meeting is a tribute to the work of many people, including the BSTP Council and Education Sub-Committee. However, I would particularly like to thank the Scientific Organisers, Stephanie Klein and Will Redfern, for their ideas and energy in successfully combining morphologic and functional aspects of cardiovascular toxicology. This was the aspiration of the meeting and I think it has been fulfilled. We know that much scientific progress is made at the intersection of different disciplines, and the BSTP is keen to establish fruitful collaborations with many other societies. This results in meetings of wider interest and allows for hot topics at the edge of our current understanding to be discussed. This meeting, organised with Jean-Pierre Valentin of the SPS, very much exemplifies this approach and I hope it forms the template of many more to come.
    [Show full text]
  • Charles Darwin House, 12 Roger St, London WC1N 2JU Tel: +44 (0)20 7685 2550 [email protected]
    The Royal Society of Biology Register of Eligible Qualified Persons – Web Version Copyright © 2013 The Royal Society of Biology All rights reserved No part of this register may be reproduced, copied or transmitted in any form or by any means without written permission from the Royal Society of Biology Anyone wishing to use details from the Register must contact the Professional Registers Programme Manager BAKER, C CBiol MRSB QualiPharm Consultancy Ltd Tel: 07968 266691 Email: [email protected] Website: www.qualipharm.co.uk Registered 2007 BARNARD DD, CBiol Holly Lodge LLantilio Crossenny Monmouthshire NP7 8TF Registered 1992 BERLANGA H, CBiol MRSB Allergy Therapeutics plc Dominion Way | Worthing West Sussex BN14 8SA Tel: 01903 844 703 Email: [email protected] Website: www.allergytherapeutics.com Registered 2011 BIRCH I, CBiol MRSB BECO Integrated Services Ltd Email: [email protected] Charles Darwin House, 12 Roger St, London WC1N 2JU Tel: +44 (0)20 7685 2550 [email protected] www.rsb.org.uk Registered Charity No.277981 Incorporated by Royal Charter Registered 2010 BURROWS M, MRSB Shire Pharmaceuticals Ireland Ltd Miesian Plaza 50 -58 Lower Baggot Street Dublin DO2 Y754 Tel: 0877112159 Email: [email protected] Registered 2015 CALLAGHAN M, MRSB Piramal Pharma Solutions Email: [email protected] CHESTERTON NJ, MRSB Dolby Vivisol Unit 18 Arkwright Road Bedford Bedfordshire MK42 0LQ Tel: 07584 086330 Email: [email protected] Registered 2011 CLACK S, CBiol MRSB Quaph Consulting
    [Show full text]
  • Impact of the Disinvestment by Astrazeneca at Alderley Park, Cheshire Volume 1: Economic Impact Assessment Final Report
    Impact of the disinvestment by AstraZeneca at Alderley Park, Cheshire Volume 1: Economic Impact Assessment Final Report Commercial in Confidence 29 January 2014 Impact of the disinvestment by AstraZeneca at Alderley Park, Cheshire Volume 1: Economic Impact Assessment Contents Executive Summary .................................................................................................................. i 1. Introduction .......................................................................................................................... 1 2. Setting the Scene ................................................................................................................. 4 3. Research Method & Impact Parameters .......................................................................... 13 4. The Quantitative Contribution of AstraZeneca at Alderley Park – ‘pre-disinvestment ’ ................................................................................................................................................. 22 5. The Quantitative Contribution of AstraZeneca at Alderley Park – ‘post-disinvestment ’ ................................................................................................................................................. 33 6. The Wider Qualitative effects of disinvestment .............................................................. 37 7. Perspectives on the Spatial Effects and Consequences of Disinvestment ................. 43 8. Conclusions & Recommendations ..................................................................................
    [Show full text]
  • The Impact of the Disinvestment by Astrazeneca at Alderley Park, Cheshire Final Report Contents
    The i mpact of the disinvestment by AstraZeneca at Alderley Park, Cheshire Volume 2: Future Market Demand Assessment Final Report Commercial in Confidence 11 February 2014 The impact of the disinvestment by AstraZeneca at Alderley Park, Cheshire Final Report Contents Executive Summary .................................................................................................................. i 1. Introduction .......................................................................................................................... 1 2. Setting the Scene ................................................................................................................. 5 3. Thinking & Planning for Demand ..................................................................................... 30 4. Projection 1 – An Initial Perspective on Demand ........................................................... 43 5. Qualitative Perspectives on Demand – the General View ............................................. 53 6. Qualitative Perspectives on Demand – the particular case of HE and Research Institutes ................................................................................................................................. 72 7. Projection 2 - A Revised Perspective on Demand .......................................................... 78 8. The Story of Existing and Pipeline Supply ...................................................................... 81 9. A Forward View of Economic Impact ..............................................................................
    [Show full text]
  • 022405Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022405Orig1s000 PHARMACOLOGY REVIEW(S) MEMORANDUM Vandetanib Date: March 25, 2011 To: File for NDA 22405 From: John K. Leighton, PhD, DABT Associate Director for Pharmacology/Toxicology Office of Oncology Drug Products I have examined pharmacology/toxicology supporting review and labeling provided by Drs. Gehrke and Dorsam and supervisory memorandum provided by Dr. Verbois. I concur with their conclusions that vandetanib may be approved for the proposed indication with the carcinogenicity studies to be provided as described in the Action Letter. Reference ID: 2923639 --------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- JOHN K LEIGHTON 03/25/2011 Reference ID: 2923639 MEMORANDUM Date: March 25, 2011 From: S. Leigh Verbois, Ph.D. Supervisory Pharmacologist Division of Drug Oncology Products To: File for NDA #022405 Vandetinib Re: Approvability of Pharmacology and Toxicology Non-clinical studies that investigated the pharmacology and toxicology of vandetinib provided to support NDA 022405 for the treatment of patients with unresectable locally advanced or metastatic medullary thyroid cancer were reviewed in detail by Brenda Gehrke,
    [Show full text]
  • Site Selection Final Report: Alderley Park
    Cheshire East Local Plan Site Selection Final Report: Alderley Park July 2016 Contents 1 Introduction 1 2 Sustainability Appraisal 2 3 Neighbourhood Plan 2 4 Sites Assessed and Recommendation 2 Site PSS1200 2 5 Overall Conclusion (Stage 9) 6 Appendices Appendix 1: Site Map 7 Appendix 2: Traffic Light Form 9 Appendix 3: Vision and Strategic Priorities Form 16 Appendix 4: Summary of Infrastructure Providers and Statutory Consultee Comments 20 Cheshire East Local Plan Strategy: Final Site Selection Report Alderley Park 1. Introduction 1.1 The ‘Cheshire East Local Plan Strategy: Site Selection Report – Alderley Park was published as background evidence to the Cheshire East Local Plan Strategy Proposed Changes Version (LPS) consultation, which took place from 4 March to 19 April 2016. The Report documented the implementation of the Site Selection Methodology (SSM) for Alderley Park. 1.2 This Report considers: (i) any additional information that has been submitted, in relation to the site and whether such information means that the conclusion and recommendation, using the SSM should change, in relation to the site; (ii) the responses, relating to the site, submitted to the public consultation in March/April 2016. 1.3 This Report supersedes the March 2016 Report; it makes it clear where circumstances have changed in relation to the site and makes recommendations accordingly, some of which may be different to those made in the March 2016 Report. 1.4 This Report should be read alongside the SSM report (and its associated evidential documents, including the Urban Potential Assessment (UPA) [PS E039b], and Edge of Settlement Assessment (ESA) [PS E039b]), the Sustainability Appraisal (SA)/Habitats Regulations Assessment (HRA), and the Cheshire East Council Proposed Changes to the Local Plan Strategy (Consultation Draft) February 2016.
    [Show full text]
  • Organization Name Add1 Add2 Add3 City A. Menarini Diagnostics Ltd Wharfedale Road Winnersh Wokingham Berkshire A1 Pharmaceutical
    Organization Name Add1 Add2 Add3 City A. Menarini Diagnostics Ltd Wharfedale Road Winnersh Wokingham Berkshire A1 Pharmaceuticals Plc Units 3/4 Bessemer Park Ind.Est 250 Milkwood Road Herne Hill London AAF Bassington Lane Cramlington Northumbeland AAH Medical Unit 20 - Broombank Business Park Broombank Rd. Sheepbridge Chesterfield Derbyshire AAH Pharmaceuticals Ltd Walsgrave Triangle Walsgrave Coventry West Midlands Abbott Laboratories Limited Abbott House Norden Road Maidenhead Berks Aber Instruments Ltd Science Park Aberystwyth Aberystwyth Abertec Ltd The Old College Kings Street Aberystwyth Aberystwyth abtec Biologicals Ltd 396 Scotland Road Taylor Street I E Liverpool Merseyside Acambis PLC Peterhouse Technology Park 100 Fulbourn Road Cambridge Cambridgeshire Actinova Ltd 5 Signet Court Swanns Road Cambridge Cambs Adams Healthcare Ltd Lotherton Way Garforth Leeds Adaptive Biosystems Ltd 15 Ribocon Way Progress Business Park Luton Beds Adelphi (Tubes) Ltd Millgreen Road Haywards Heath West Sussex Advanced Biotechnologies Ltd Unit Units B1 & B2 Longmead Business Centre Blenheim Road Surrey Epsom Advanced Medical Solutions Group Plc Road Three Winsford Industrial Estate Windsford Cheshire Advanced Technologies (Cambridge) Ltd (ATC) 210 Cambridge Science Park Milton Road Cambridge Cambs Advante Holdings (UK) Ltd Plant Breeding Station Boothby Graffoe Lincs Aea Technology Biotechnology Services 353 Harwell Didcot Oxfordshire AEA Technology plc AEA Technology Biosciences F4 Culham Science Centre Abingdon Oxon AERES Biomedical Ltd 1-3 Burtonhole
    [Show full text]